Paratek Pharmaceuticals Presents Data Supporting Potential Approval of Omadacycline for Treatment of Community-Acquired Bacterial Pneumonia Based on the EMA Guidelines at ECCMID

Company on track to file marketing authorization applications in the European Union in the second half of 2018
Data on utility in geographic regions also presented
MADRID, Spain, April 23, 2018 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) presented an analysis of data from the Company’s Phase 3 OPTIC study of omadacycline vs. moxifloxacin for the treatment of community-acquired bacterial pneumonia (CABP) using the European Medicines Agency (EMA) guidance for approval of new treatments for CABP.  Omadacycline is an investigational once-daily oral and intravenous (IV) monotherapy antibiotic for the treatment of community-acquired infections including CABP and acute bacte…


Leave a Reply

Your email address will not be published.